SURPASS-2 (nejm.org)
Peer-reviewed paperOzempic injection vs Mounjaro
Adults with type 2 diabetes inadequately controlled with metformin.
1,879 participants · 40 weeks (nejm.org/doi/full/10.1056/NEJMoa2107519) · Randomized, open-label
Mean HbA1c change (percentage points)
Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.
| Treatment & dose | Change |
|---|---|
| Semaglutide (Ozempic)1 mg weekly injection | −1.86 pp (nejm.org) |
| Tirzepatide (Mounjaro)5 mg weekly injection | −2.01 pp (nejm.org) |
| Tirzepatide (Mounjaro)10 mg weekly injection | −2.24 pp (nejm.org) |
| Tirzepatide (Mounjaro)15 mg weekly injection | −2.3 pp (nejm.org) |
Each tirzepatide dose lowered HbA1c more than semaglutide 1 mg in this trial.
This trial did not compare Ozempic 2 mg or tablets. HbA1c changes are percentage points, not relative percentages or weight-loss results. Study averages do not predict an individual's result.